Eric Ranon, MD
Internal Medicine · Rogers, ARNPI 1861476137
Payments from drug & device makers
Across 145 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$457
- Lilly USA, LLC$264
- Merck$242
- Novo Nordisk$225
- Novartis$168
- AstraZeneca$133
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,62698%
- Education$482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $457 |
| Lilly USA, LLC | 15 | $264 |
| Merck | 13 | $242 |
| Novo Nordisk | 14 | $225 |
| Novartis | 10 | $168 |
| AstraZeneca | 9 | $133 |
| Bayer | 7 | $125 |
| Abbott | 6 | $124 |
| Pfizer | 5 | $86 |
| Scilex Pharmaceuticals Inc. | 5 | $85 |
| Dexcom, Inc. | 5 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $77 |
| Amgen | 3 | $68 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Astellas Pharma US Inc | 3 | $53 |
| Exact Sciences | 2 | $49 |
| Medtronic(2 entities) | 2 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Evoke Pharma, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Lifescan, Inc. | 2 | $35 |
| GSK | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Smith+Nephew | 1 | $14 |
How this compares
$2,674 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 318 | $219,762 |
| JardianceEmpagliflozin | 288 | $210,507 |
| OzempicSemaglutide | 189 | $183,368 |
| JanuviaSitagliptin Phosphate | 222 | $158,013 |
| FarxigaDapagliflozin Propanediol | 144 | $116,366 |
| Humira PenAdalimumab | 14 | $112,811 |
| XareltoRivaroxaban | 155 | $106,459 |
| TrulicityDulaglutide | 76 | $91,173 |
| EntrestoSacubitril/Valsartan | 106 | $88,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $76,594 |
| Spiriva RespimatTiotropium Bromide | 80 | $49,247 |
| SymbicortBudesonide/Formoterol Fumarate | 132 | $35,898 |
| Advair HfaFluticasone Propion/Salmeterol | 98 | $34,457 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,142 | $30,669 |
| MounjaroTirzepatide | 29 | $30,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $37 | $275,193401 claims |
| PfizerEliquis, Lyrica | $86 | $229,149336 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta, Breztri Aerosphere | $133 | $189,777339 claims |
| Novo NordiskOzempic | $225 | $183,368189 claims |
| MerckJanuvia | $242 | $158,013222 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $33 | $122,956214 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $264 | $121,605105 claims |
| NovartisEntresto | $168 | $88,362106 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $27,39839 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $57 | $20,53971 claims |
| AbbVieLinzess | $457 | $14,25327 claims |
| Esperion Therapeutics, Inc.Nexletol | $16 | $12,92229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Rogers
- Kathleen GannonRogers$450K
- Stuart BensonRogers$24K
- Douglas EddyRogers$9K
- Ruben TejadaRogers$6K
- Kristy JonesRogers$6K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
- Alexander KaczenskiLittle Rock$305K
- John HendersonSearcy$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.